Insider Trading
Current insider transactions (SEC Form 4) — buys and sells by officers, directors, and major shareholders.
| Ticker | Insider | Title | Date | Transaction | Price ($) | Shares | Value ($) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ROIV | Venker Eric | President & Immunovant CEO | 10/28/2026 | Verkauf | 36.59 | 200,000 | 7,318,000 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10/23/2026 | Steuer-Abgabe | 36.49 | 116 | 4,233 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10/23/2026 | Zuteilung | — | 513 | — | Form 4 |
| ROIV | Oren Ilan | Director | 10/23/2026 | Zuteilung | — | 810 | — | Form 4 |
| ROIV | Momtazee James C | Director | 10/23/2026 | Steuer-Abgabe | 36.49 | 77 | 2,810 | Form 4 |
| ROIV | Momtazee James C | Director | 10/23/2026 | Zuteilung | — | 383 | — | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 10/20/2026 | Verkauf | 35.42 | 14,144 | 500,980 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 10/20/2026 | Verkauf | 35.09 | 185,856 | 6,521,687 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 10/16/2026 | Steuer-Abgabe | 33.53 | 19,976 | 669,795 | Form 4 |
| ROIV | Gline Matthew | CEO | 10/16/2026 | Steuer-Abgabe | 33.53 | 34,638 | 1,161,412 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10/01/2026 | Verkauf | 36.57 | 900 | 32,913 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10/01/2026 | Verkauf | 36.08 | 16,850 | 607,948 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 10/01/2026 | Optionsausübung | 4.46 | 17,750 | 79,165 | Form 4 |
| ROIV | Roivant Sciences Ltd. | Director | 10/01/2026 | Abgabe | 5.00 | 8,967,383 | 44,836,915 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 09/30/2026 | Steuer-Abgabe | 36.57 | 46,879 | 1,714,365 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 09/30/2026 | Verkauf | 36.62 | 200,000 | 7,324,000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 09/30/2026 | Optionsausübung | 3.85 | 200,000 | 770,000 | Form 4 |
| ROIV | Gline Matthew | CEO | 09/30/2026 | Steuer-Abgabe | 36.57 | 76,171 | 2,785,573 | Form 4 |
| ROIV | Torti Frank | President and Vant Chair | 09/30/2026 | Steuer-Abgabe | 36.57 | 40,309 | 1,474,100 | Form 4 |
| ROIV | Pulik Richard | CFO | 09/20/2026 | Steuer-Abgabe | 39.77 | 2,129 | 84,670 | Form 4 |
| ROIV | Humes Jennifer | Chief Accounting Officer | 09/20/2026 | Steuer-Abgabe | 39.77 | 3,880 | 154,308 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Gold Daniel Allen | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Oren Ilan | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Momtazee James C | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Manchester Keith S | Director | 09/16/2026 | Zuteilung | — | 5,054 | — | Form 4 |
| ROIV | Epperly Melissa B, | Director | 09/15/2026 | Verkauf | 40.38 | 600 | 24,228 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 09/15/2026 | Verkauf | 39.65 | 4,338 | 172,002 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/15/2026 | Verkauf | 40.45 | 400 | 16,180 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/15/2026 | Verkauf | 39.68 | 4,712 | 186,972 | Form 4 |
| ROIV | Epperly Melissa B, | Director | 09/10/2026 | Steuer-Abgabe | 40.94 | 2,179 | 89,208 | Form 4 |
| ROIV | Oren Ilan | Director | 09/10/2026 | Steuer-Abgabe | 40.94 | 2,378 | 97,355 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/10/2026 | Steuer-Abgabe | 40.94 | 1,743 | 71,358 | Form 4 |
| ROIV | Momtazee James C | Director | 09/10/2026 | Steuer-Abgabe | 40.94 | 2,905 | 118,931 | Form 4 |
| ROIV | Gold Daniel Allen | Director | 09/10/2026 | Steuer-Abgabe | 40.94 | 5,133 | 210,145 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/08/2026 | Verkauf | 39.90 | 20,000 | 798,000 | Form 4 |
| ROIV | Fitzgerald Meghan | Director | 09/08/2026 | Optionsausübung | 8.80 | 20,000 | 176,000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 08/28/2026 | Verkauf | 36.44 | 33,818 | 1,232,328 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 08/28/2026 | Verkauf | 35.63 | 166,182 | 5,921,065 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 08/28/2026 | Optionsausübung | 3.85 | 200,000 | 770,000 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/21/2026 | Verkauf | 36.48 | 144,756 | 5,280,699 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/21/2026 | Optionsausübung | 3.85 | 144,756 | 557,311 | Form 4 |
| ROIV | Pulik Richard | CFO | 08/20/2026 | Steuer-Abgabe | 36.84 | 5,749 | 211,793 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 08/20/2026 | Steuer-Abgabe | 36.84 | 13,909 | 512,408 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/20/2026 | Verkauf | 37.30 | 17,519 | 653,459 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/20/2026 | Optionsausübung | 3.85 | 17,519 | 67,448 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/19/2026 | Verkauf | 37.17 | 172,899 | 6,426,656 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/19/2026 | Optionsausübung | 3.85 | 172,899 | 665,661 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/18/2026 | Verkauf | 37.18 | 31,801 | 1,182,361 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/18/2026 | Optionsausübung | 3.85 | 31,801 | 122,434 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/18/2026 | Verkauf | 36.59 | 105,141 | 3,847,109 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/18/2026 | Optionsausübung | 3.85 | 105,141 | 404,793 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/17/2026 | Verkauf | 36.25 | 284,707 | 10,320,629 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/17/2026 | Optionsausübung | 3.85 | 284,707 | 1,096,122 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/14/2026 | Verkauf | 36.23 | 243,177 | 8,810,303 | Form 4 |
| ROIV | Sukhatme Mayukh | President & CIO | 08/14/2026 | Optionsausübung | 3.85 | 243,177 | 936,231 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 07/27/2026 | Verkauf | 34.95 | 200,000 | 6,990,000 | Form 4 |
| ROIV | Venker Eric | President & Immunovant CEO | 07/27/2026 | Optionsausübung | 3.85 | 200,000 | 770,000 | Form 4 |
| ROIV | Momtazee James C | Director | 07/17/2026 | Zuteilung | — | 405 | — | Form 4 |
A compact market overview — not investment advice. Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q).